Skip to main content
NewslettersWatchlist

Merrimack Pharmaceuticals Inc(MACK-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low14.99
Day High15.03
Open:15.02
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
BayStreet.ca
The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm
PR Newswire
Pancreatic Cancer Battle Boosted by $200M VC Firm
Business Wire
Merrimack Reports First Quarter 2023 Financial Results
Business Wire
Merrimack Reports Full Year 2022 Financial Results
Business Wire
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan
BayStreet.ca
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
PR Newswire
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
Business Wire
Merrimack Provides Ipsen Report That Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Business Wire
Merrimack Reports Third Quarter 2022 Financial Results
Business Wire
Merrimack Reports Second Quarter 2022 Financial Results
Business Wire
Merrimack Provides Ipsen Report of Results From Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
Business Wire
Merrimack Reports First Quarter 2022 Financial Results
Business Wire
Merrimack Reports Third Quarter 2021 Financial Results
Business Wire
Merrimack Reports Second Quarter 2021 Financial Results
Globe NewsWire
180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors
Business Wire
Merrimack Reports Full Year 2020 Financial Results
Business Wire
Merrimack Reports Third Quarter 2020 Financial Results
Business Wire
Merrimack Reports Second Quarter 2020 Financial Results
Business Wire
Merrimack Reports First Quarter 2020 Financial Results

Profile

Merrimack Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and preparation to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with a special focus on cancer. Merrimack Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.